IL2 and neoplasm: Since solely anti-PD-L1 improved the response of LLC tumors to RT+L19–IL2, we performed mechanistic studies to investigate the tumor immune landscape generated after delivering the aforementioned treatments to LLC tumor-bearing mice (figure 2A).